<DOC>
	<DOCNO>NCT01998841</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , parallel group , adaptive study evaluate efficacy safety crenezumab versus placebo individual carry PSEN1 E280A autosomal-dominant mutation meet criterion mild cognitive impairment due AD dementia due AD , thus , preclinical phase AD . Participants randomize 1:1 receive either crenezumab placebo subcutaneously every 2 week 260 week . The study also include cohort PSEN1 E280A mutation noncarriers dose placebo .</brief_summary>
	<brief_title>A Study Crenezumab Versus Placebo Preclinical Presenilin1 ( PSEN1 ) E280A Mutation Carriers Evaluate Efficacy Safety Treatment Autosomal-Dominant Alzheimer Disease ( AD ) , Including Placebo-Treated Noncarrier Cohort</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Membership PSEN1 E280A mutation carrier kindred Agrees condition , willing undergo , genetic testing ( example [ e.g . ] , apolipoprotein E [ APOE ] , PSEN1 E280A , genetic testing ) PSEN1 E280A mutation carrier noncarrier status confirm prior screen period MiniMental Stage Examination ( MMSE ) great equal ( &gt; = ) 24 participant less ( &lt; ) 9 year education MMSE &gt; =26 participants 9 year education Does meet criterion dementia due AD per National Institute Aging Alzheimer 's Association Workgroup ( McKhann et al . 2011 ) Criteria Does meet criterion mild cognitive impairment ( MCI ) due AD per The National Institute Aging Alzheimer 's Association Workgroup ( Albert et al . 2011 ) Criteria Adequate vision hear investigator 's judgment able complete test If female , document ( medical record physician 's note ) surgically sterile ( absence ovary and/or uterus ) postmenopausal , willing undergo pregnancy test protocolspecific timepoints For woman document ( medical record physician 's note ) surgically sterile ( absence ovary and/or uterus ) postmenopausal , agreement remain abstinent use two adequate method contraception , include least one method failure rate &lt; 1 % per year ( e.g. , hormonal implant , combine oral contraceptive , vasectomized partner , tubal ligation ) treatment period least 16 week last dose study drug For men partner childbearing potential ( i.e. , woman surgically sterile postmenopausal ) , agreement remain abstinent use condom method contraception treatment period least 6 week last dose study drug Study partner agree participate study capable willing : accompany participant require visit ; provide information require telephone assessment ; spend sufficient time participant familiar his/her overall function behavior able provide adequate information participant include knowledge domestic activity , hobby , routine , social skill basic activity daily life ; work educational history ; cognitive performance include memory ability , language ability , temporal spatial orientation , judgment problem solve ; emotional psychological state ; general health status Participant study partner evidence adequate premorbid functioning ( e.g. , intellectual , visual , auditory ) fluent , able read , language study assessment administer Willing able undergo neuroimaging ( PET MRI ) Serum thyroid stimulate hormone ( TSH ) B12 level within normal expect range test laboratory TSH B12 value range judged investigator clinically significant . If participant undergoing thyroid replacement therapy , TSH level must within normal expect range test laboratory , TSH value range , require therapeutic action ( treatment surveillance ) . If participant receive vitamin B12 injection oral vitamin B12 therapy , B12 level must lower limit normal test laboratory , B12 value range , require therapeutic action ( treatment surveillance ) In good general health know comorbidities expect interfere participation study Significant medical , psychiatric , neurological condition disorder document history , physical , neurological , laboratory , electrocardiogram ( ECG ) examination would place participant undue risk investigator 's judgment impact interpretation efficacy History stroke . Participants history transient ischemic attack may enrol event occur &gt; =2 year prior screen History severe , clinically significant ( persistent neurological deficit structural brain damage ) central nervous system trauma ( e.g . cerebral contusion ) Body weight &lt; 45 &gt; 120 kilogram ( kg ) History presence atrial fibrillation pose risk future stroke investigator 's judgment Clinically significant laboratory ECG abnormality ( e.g. , abnormally prolong shorten QTc interval ) investigator 's judgment Current presence bipolar disorder clinically significant major psychiatric disorder accord Diagnostic Statistical Manual Mental Disorders 4th Edition Text Revision ( DSMIVTR ) symptom ( e.g. , hallucination , agitation , paranoia ) could affect participant 's ability complete evaluation Clinically significant depression , base part Geriatric Depression Scale ( short form ) ( 15point scale ) score &gt; 9 screen History seizure ( exclude febrile seizure childhood , isolated seizure episode due epilepsy judgment investigator , require timelimited anticonvulsant treatment , occur 7 year prior screen visit ) Myocardial infarction within 2 year , congestive heart failure , atrial fibrillation , uncontrolled hypertension Pregnant nursing woman , woman intend become pregnant nurse infant conduct trial Clinically significant infection within last 30 day prior screen Positive urine test drug abuse screen History alcohol substance dependence within previous two year Use medication potential significantly affect cognition ; intermittent shortterm use medication may allow deem medically necessary treatment nonexcluded medical condition approval Medical Monitor . In addition , use tricyclic antidepressant benzodiazepine permit used stable , low dos treatment nonexcluded medical condition approval Medical Monitor Use typical antipsychotic , barbiturate , anticholinergic antidepressant unless use low dos condition depression , migraine headache , approve medical monitor Use nonanticholinergic antidepressant medication atypical antipsychotic unless maintain stable dose regimen least 6 week prior screen Use Food Drug Administration ( FDA ) /Instituto Nacional de Vigilancia de Medicamentos Alimentos ( INVIMA ) approve medication treatment late onset Alzheimer 's disease ( LOAD ) screening/baseline . Cholinesterase inhibitor and/or memantine prohibit study except participant enrol study develop AD dementia Use anticoagulant medication , except aspirin ( heparinoids , heparin , warfarin , thrombin inhibitor , Factor Xa inhibitor ) , know coagulopathy platelet count &lt; 100,000 cells/mcL , within 4 week screen visit ; Antiplatelet medication ( e.g. , aspirin , clopidigrel , dipyridamole ) permit stable dose 4 week prior screen . Shortterm , perioperative use anticoagulant may result discontinuation study ; however , use must discuss Medical Monitor . Treatment biologic therapy within five halflives 3 month prior screen , whichever longer , exception routinely recommend vaccination , allow Use antiseizure medication ( except childhood febrile seizure use nonseizure indication ) , antiparkinsonian , stimulant ( e.g. , methylphenidate ) medication Use investigational drug , device , experimental medication within 60 day ( five halflives , whichever long ) screen visit Previous treatment crenezumab therapeutic target Abeta History severe allergic , anaphylactic , hypersensitivity reaction chimeric , human , humanized antibody fusion protein Contraindication MRI scan procedure clinically significant claustrophobia would contraindicate brain MRI scan Contraindication PET scan procedure</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>